That’s the wrong question.

The right question is: what does this patient need, at this stage of their disease?

Obesity is chronic, progressive, and heterogeneous. The era of picking a lane — medical or surgical — is over. The best outcomes come from building integrated pathways. Here’s how I think we could think about it clinically.

BMI 27–35: Early intervention, metabolic protection

This is where the newer incretin therapies have genuinely expanded our toolkit. For patients without advanced complications, GLP-1s can achieve meaningful weight loss and delay progression to T2DM, NAFLD, and OSA. The goal here is prevention — getting in early before the disease accumulates damage. Medication earns its place at this stage, and I use it.

BMI 35–45: The judgment zone

No dogma here. This is where clinical decision making meets outcome data.

I’ll consider GLP-1s alone when diabetes is mild or very recently diagnosed and the patient is highly adherent. Endoscopic options when they want a lower-risk bridge with 15% total body weight loss (TBWL). Surgery when there’s severe GERD, significant visceral fat, liver fibrosis, established diabetes or a poor response to medical therapy.

Often the sequence is: surgery for the durability that drugs alone haven’t matched long-term. HbA1c, reflux burden, functional status, and what the patient can realistically sustain for 20 years, cumulative cost of injectables — these also can drive the decision for surgery versus a trial of medication, not the BMI alone.

BMI 45+: Surgery anchors the pathway

The data here hasn’t changed, and it won’t be overturned by a few years of GLP-1 trial data. For severe obesity with end-organ damage — fatty liver disease, refractory T2DM, sleep apnoea, joint destruction — metabolic surgery delivers weight loss and disease remission at a magnitude we cannot replicate pharmacologically with medications available to date. Not yet. Possibly not ever, for this cohort.

That said, GLP-1s have earned a genuine role around surgery: shrinking the liver pre-operatively in very high BMI patients, reducing anaesthetic risk, and rescuing for weight regain long after the operation. They can extend what surgery starts. They don’t replace what surgery does.

What the best programs are building

Stratify by more than BMI — we need to stratify patients by metabolic burden, genetics, psychological readiness, and social context all matter. Sequence therapies deliberately and consider what the correct combinations are based on the stage of the disease. Follow patients for decades, not months. And put surgeons, physicians, dietitians, and psychologists in the same room, sharing the same data.

The tribalism between “medical” and “surgical” camps has cost patients. The win here is designing systems that deliver the right option, to the right patient, at the right moment in their disease trajectory.

That’s precision obesity care. And it needs surgeons to build it.

Your Health. We Care.

The post Knife and Needles appeared first on Blackrock WeightCare.

Will the weight come back?

The honest answer is that weight regain can happen with both treatments. The difference lies in why it happens, how common it is, and how it is managed.

Understanding that difference matters before choosing your next step.

Why Weight Regain Happens After Injections

Medications such as Mounjaro and Ozempic work by regulating appetite hormones and slowing stomach emptying. While you are taking them, appetite is reduced and calorie intake falls.

The challenge is what happens when the medication stops.

These injections do not permanently change the anatomy of the digestive system. Once the medication is withdrawn:

• Appetite hormones gradually return to baseline
• Hunger increases
• Calorie intake rises
• Weight regain can occur

Clinical studies have shown that a significant proportion of weight lost on GLP-1 medications may be regained after stopping treatment if no structured long-term plan is in place.

This means injections need to be continued long term to maintain results. Medication is a lifelong treatment for a chronic disease. That carries a commitment to continuing the medications with clear cost implications and requires ongoing medical supervision.

Why Weight Regain Happens After Bariatric Surgery

Weight regain after surgery is different.

Procedures such as Gastric Sleeve and SADI-S permanently alter stomach size and, in some cases, nutrient absorption. They also create long-lasting hormonal changes that reduce hunger and improve insulin sensitivity.

However, surgery is not immune to weight regain.

Reasons may include:

• Gradual adaptation of the stomach over time
• High-calorie liquid intake
• Grazing behaviour
• Emotional eating
• Reduced follow-up engagement
• Lack of dietary structure

The key difference is that the anatomical and hormonal changes from surgery remain in place. This makes weight regain generally slower and often less dramatic than after stopping injections.

In most cases, surgery provides more durable long-term weight loss, particularly in patients with BMI over 45.

How Much Weight Regain Is Normal

After bariatric surgery, small amounts of weight regain several years later can be normal. The body stabilises after the initial weight loss phase. The goal is not zero regain. The goal is maintaining significant net weight loss and improvement in health.

After stopping injections, weight regain can be more rapid because the hormonal effect is removed entirely.

The pattern is different. The underlying biology explains why.

Which Offers More Durable Results

For patients with severe obesity, especially BMI above 40, bariatric surgery consistently shows stronger and more durable long-term outcomes compared to injections alone.

Injections can be effective for moderate obesity. They are valuable tools. But they do not currently match the long-term metabolic impact of surgery in higher BMI groups. That does not mean injections have no role. In some patients, they are appropriate as:

• A primary treatment
• A bridge before surgery
• Support in cases of mild post-surgical regain

For many patients the treatment of their obesity may involve both – often surgery now and medication later if ever required.

The decision depends on the individual.

What Happens if Weight Regain Occurs

At Blackrock WeightCare, weight regain is managed proactively.

This may include:

• Nutritional review
• Behavioural support
• Medical optimisation
• Use of medication where appropriate
• Consideration of revisional surgery in selected cases

Mr William Robb assesses each situation carefully. As an Upper GI and Robotic Bariatric Surgeon, he evaluates anatomical, metabolic and behavioural factors before recommending next steps.

The focus is always on long-term health, not short-term numbers.

The Bigger Question

The real question is not whether weight regain is possible. It is which treatment offers the most sustainable control of a chronic disease.

Obesity is a long term chronic disease. It requires a long-term plan and an ever evolving algorithm of care.

Injections require ongoing use to maintain effect. Surgery creates permanent anatomical and hormonal changes that support durability, particularly in higher BMI patients.

Neither is a quick fix. Both require commitment and follow-up.

Choosing the Right Path

If you are concerned about weight regain, whether after injections or surgery, the right step is expert assessment before making changes.

At Blackrock WeightCare, complex and high BMI patients are routinely assessed to determine the safest and most effective long-term strategy.

To know more, click here and fill the enquiry form or speak directly with our team on 01 255 2479.

Your Health. We Care.

The post Weight Regain After Injections vs Bariatric Surgery: What is the Difference appeared first on Blackrock WeightCare.